Neurotechnology

ONWARD Medical

Medium0/2 relationships sourcedProfile verified Aug 10, 2026

30-Second Executive Brief

Executive Assessment

ONWARD Medical functions as a regional institution within Neurotechnology, backed by 0% sourcing coverage, with a stable competitive position.

  • Maintains 2 mapped relationships across the graph
  • 0% sourcing coverage across sourced relationships
  • Tracked as regional institution within the Neurotechnology category

Executive Snapshot

Strategic Role
Regional Institution
Sourcing Coverage
0%
View Methodology →

Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.

Ecosystem Influence
Moderate
Strategic Momentum
Insufficient Data

Coverage

Mapped Relationships
2
Technology Domains
2

Strategic Implications

  • Central node connecting multiple strategic ecosystems
  • Directly influences technology and capital flows
  • Material relevance to downstream dependency mapping

Top Opportunities

Expanding home-use access following FDA clearance, broadening the addressable patient population beyond clinical settings.

Top Risks

Commercial adoption of home-use neurostimulation devices depends on insurance reimbursement and patient uptake.

Critical Dependencies

Continue to Dependency Graph ↓

ONWARD Medical develops neurostimulation therapies to restore movement and function after spinal cord injury. In November 2025 ONWARD received FDA 510(k) clearance for its external ARC-EX system for home use, a non-invasive spinal cord stimulation device that had previously been used only in clinical settings.

Sources

Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.

Evidence

1 source

Acquisition & Investment Fit

AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.

Relationship Map

The relationships surrounding ONWARD Medical — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.

Connection type

Sign in free to click a node and explore →

Click any node to make it the new center. Scroll to zoom, drag to pan.

The Story So Far

Nov 2025: FDA clears ONWARD's ARC-EX system for home useNov 2025: ONWARD Receives FDA Clearance for Home-Use ARC-EX System

Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.

ONWARD Medical's Timeline

A sourced, dated history of ONWARD Medical's key moments — founding to present.

  1. Nov 2025 · FDA clears ONWARD's ARC-EX system for home use

    ONWARD received FDA 510(k) clearance for its external ARC-EX spinal cord stimulation system for home use, expanding access beyond clinical settings.